<DOC>
	<DOCNO>NCT01628536</DOCNO>
	<brief_summary>The investigator hypothesize black cohosh , potentially therapeutic agent , reduce overall size aggressiveness ductal carcinoma situ ( DCIS ) give pre-operative setting .</brief_summary>
	<brief_title>A Pilot Pre-operative Window Trial Black Cohosh Women With Ductal Carcinoma Situ</brief_title>
	<detailed_description>The overarch hypothesis research black cohosh potential well-tolerated , effective agent treatment early breast cancer . This pilot study represent first step explore hypothesis demonstrate preliminary evidence specific anti-tumor effect black cohosh area ductal carcinoma situ ( DCIS ) breast .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<criteria>A patient/subject eligible enrollment follow inclusion criterion meet : 1 . Pre postmenopausal woman ≥ 18 year age newly diagnose DCIS histologically confirm breast core biopsy 2 . Ability understand willingness sign write informed consent document 3 . ECOG performance status 01 4 . Life expectancy &gt; 12 month 5 . Willing schedule definitive resection DCIS 4 week +/ 1 week study enrollment 6 . Original breast core biopsy specimen available pathologic review stain Yale School Medicine Department Pathology A patient /subject eligible study follow exclusion criterion meet : 1 . Pregnant nursing within past 6 month 2 . Lactose intolerant , lactose allergy salicylate allergy 3 . Patients already undergone excisional biopsy qualify DCIS 4 . Patients ipsilateral treatment DCIS breast cancer within 12 month prior enter study 5 . Patients receive chemotherapy investigational agent 6 . Serious concomitant systemic disorder ( include active infection ) psychiatric illness/social situation would compromise safety patient compromise patient 's ability complete study , discretion investigator . 7 . Liver function test ≥ 20 % institutional upper limit normal 8 . Creatinine &gt; 1.5 time institutional upper limit normal 9 . ANC &lt; 1,500 /µL 10 . Platelets &lt; 100,000 /µL 11 . History allergic reaction attribute compound similar chemical biologic composition black cohosh 12 . The effect black cohosh develop human fetus recommend therapeutic dose unknown . For reason , woman childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 13 . Prior/concurrent therapy include : Tamoxifen , raloxifene , letrozole , anastrozole , exemestane past 6 month 14 . Chemotherapy , biologic therapy ( e.g. , trastuzumab [ Herceptin® ] ) , breast radiotherapy breast currently affect DCIS within past 12 month 15 . Any exogenous hormonal therapy include estrogen , progesterone , and/or androgenbased agent past 6 month 16 . Phytoestrogens OTC medication estrogenic androgenic property past 6 month 17 . Any black cohosh preparation within past 6 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Black Cohosh</keyword>
	<keyword>Ductal Carcinoma situ</keyword>
	<keyword>Breast Cancer</keyword>
</DOC>